Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization

Trial Profile

Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Feb 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Immediate hypersensitivity
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Feb 2018 Status changed from recruiting to completed.
    • 06 Feb 2017 Planned number of patients changed from 20 to 10.
    • 22 Jul 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top